Search details
1.
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
N Engl J Med
; 386(26): 2482-2494, 2022 06 30.
Article
in English
| MEDLINE | ID: mdl-35657079
2.
Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study.
Haematologica
; 107(7): 1633-1642, 2022 07 01.
Article
in English
| MEDLINE | ID: mdl-34407602
3.
Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET/CT: an analysis of a prospective trial.
BMC Cancer
; 22(1): 403, 2022 Apr 13.
Article
in English
| MEDLINE | ID: mdl-35418080
4.
Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera® ) in combination with CHOP in patients with previously untreated CD20-positive diffuse large B-cell lymphoma: A randomized, single-blind, phase III clinical trial.
Hematol Oncol
; 40(5): 930-940, 2022 Dec.
Article
in English
| MEDLINE | ID: mdl-35858181
5.
A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera®) in patients with CD20-positive B-cell non-Hodgkin lymphoma.
Chin J Cancer Res
; 34(6): 601-611, 2022 Dec 30.
Article
in English
| MEDLINE | ID: mdl-36714342
6.
Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy.
Blood
; 133(2): 137-146, 2019 01 10.
Article
in English
| MEDLINE | ID: mdl-30341058
7.
Phase 1 studies comparing safety, tolerability, pharmacokinetics and pharmacodynamics of HLX01 (a rituximab biosimilar) to reference rituximab in Chinese patients with CD20-positive B-cell lymphoma.
Chin J Cancer Res
; 33(3): 405-416, 2021 Jun 30.
Article
in English
| MEDLINE | ID: mdl-34321836
8.
Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.
N Engl J Med
; 372(10): 944-53, 2015 Mar 05.
Article
in English
| MEDLINE | ID: mdl-25738670
9.
Phase II study of doxorubicin and thalidomide in patients with refractory aggressive fibromatosis.
Invest New Drugs
; 36(1): 114-120, 2018 02.
Article
in English
| MEDLINE | ID: mdl-29170886
10.
A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer.
BMC Cancer
; 17(1): 188, 2017 03 14.
Article
in English
| MEDLINE | ID: mdl-28288572
11.
[Efficacy and safety of rituximab combined with CHOP or combined with dose fractionated CHOP in the treatment of primary gastric diffuse large B cell lymphoma].
Zhonghua Zhong Liu Za Zhi
; 36(12): 939-43, 2014 Dec.
Article
in Zh
| MEDLINE | ID: mdl-25623771
12.
Predicting central nervous system relapse in primary breast diffuse large B-cell lymphoma using the stage-modified IPI score: A retrospective cohort study.
Heliyon
; 10(5): e26795, 2024 Mar 15.
Article
in English
| MEDLINE | ID: mdl-38439878
13.
IRF4 rearrangement may predict favorable prognosis in children and young adults with primary head and neck large B-cell lymphoma.
Cancer Med
; 12(9): 10684-10693, 2023 05.
Article
in English
| MEDLINE | ID: mdl-37081786
14.
Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study.
Hemasphere
; 7(7): e919, 2023 Jul.
Article
in English
| MEDLINE | ID: mdl-37404773
15.
Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
Ann Hematol
; 91(6): 837-45, 2012 Jun.
Article
in English
| MEDLINE | ID: mdl-22160255
16.
Blastic plasmacytoid dendritic cell neoplasm without cutaneous lesion at presentation: case report and literature review.
Acta Haematol
; 127(2): 124-7, 2012.
Article
in English
| MEDLINE | ID: mdl-22236870
17.
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
Lancet Oncol
; 12(8): 773-84, 2011 Aug.
Article
in English
| MEDLINE | ID: mdl-21724462
18.
Prognostic significance of clinical characteristics and 18Fluorodeoxyglucose-positron emission tomography/computed tomography quantitative parameters in patients with primary mediastinal B-cell lymphoma.
J Int Med Res
; 50(1): 3000605211063027, 2022 Jan.
Article
in English
| MEDLINE | ID: mdl-35001690
19.
Hexokinase II expression as a prognostic marker in diffuse large B-cell lymphoma: pre- and post-rituximab era.
Int J Hematol
; 116(3): 372-380, 2022 Sep.
Article
in English
| MEDLINE | ID: mdl-35536508
20.
Clinical Characteristics and Prognostic Factors in Primary Breast Diffuse Large B-Cell Lymphoma.
Mediterr J Hematol Infect Dis
; 14(1): e2022066, 2022.
Article
in English
| MEDLINE | ID: mdl-36119461